Bristol Myers Squibb

News

FDA sets November review date for J&J's multiple myeloma CAR...

Johnson & Johnson has secured a six-month FDA review for its multiple myeloma CAR-T therapy ciltacabtagene autoleucel (cilta-cel), narrowing the lead for Bristol-Myers Squibb and bluebi

News

Science Molecule, Molecular DNA Model Structure, business teamwork conceptMolecular, DNA and atom model in science research labMolecular, DNA and atom model in science research lab setting in studio.

BMS embraces AI drug discovery with $1.2bn Exscientia allian...

Exscientia has signed up another big pharma partner for its artificial intelligence (AI) based drug discovery platform, this time attracting a $50 million upfront buy-in from Bristol-Myers

News

LAG-3 drugs take centre stage at ASCO, showing potential as ...

LAG-3 drugs from arch-rivals Bristol-Myers Squibb and Merck & Co look set to become talking points at this year's ASCO conference after trial results showed their potential as next-gene

News

BMS agrees deal worth up to $1.56bn for Agenus' TIGIT cancer...

Bristol-Myers Squibb has paid $200 million, and promised up to $1.36 billion in “biobucks” for exclusive rights to a cancer antibody still in the labs of US biotech Agenus, which blocks the

News

Keytruda should lose stomach cancer indication, says ODAC

The FDA's Oncologic Drugs Advisory Committee (ODAC) has voted to strip Merck & Co's Keytruda of its accelerated approval in gastric and gastroesophageal junction (GEJ) cancer, despite a

News

FDA looks at pulling speedy approvals for three cancer drugs

FDA advisors will scrutinise three cancer immunotherapies granted conditional approvals at a three-day meeting this week, to see if they should stay on the market.

FDA sets November review date for J&J's multiple myeloma CAR...

BMS embraces AI drug discovery with $1.2bn Exscientia allian...

LAG-3 drugs take centre stage at ASCO, showing potential as ...

BMS agrees deal worth up to $1.56bn for Agenus' TIGIT cancer...

Keytruda should lose stomach cancer indication, says ODAC

FDA looks at pulling speedy approvals for three cancer drugs

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Bristol Myers Squibb

Editor's Picks